Edward Meyers, MD
Emergency Medicine · Sumter, SCNPI 1083631618
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 9.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $767 and has fallen 84.6% since, to $118 in 2025. Among emergency medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 147 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$215
- Bayer$191
- AbbVie$185
- Amgen$155
- Pfizer$129
- Esperion Therapeutics, Inc.$128
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,225100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $215 |
| Bayer | 10 | $191 |
| AbbVie | 19 | $185 |
| Amgen(2 entities) | 11 | $155 |
| Pfizer | 10 | $129 |
| Esperion Therapeutics, Inc. | 8 | $128 |
| Novartis | 9 | $127 |
| Biohaven Pharmaceuticals, Inc. | 6 | $115 |
| Novo Nordisk | 7 | $101 |
| Sanofi-aventis U.S. LLC | 5 | $77 |
| AstraZeneca | 5 | $70 |
| Indivior Inc. | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Genentech USA, Inc. | 4 | $47 |
| Boehringer Ingelheim | 3 | $47 |
| Jazz Pharmaceuticals Inc. | 3 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $42 |
| Merck | 3 | $41 |
| Alnylam Pharmaceuticals Inc. | 2 | $37 |
| Ardelyx, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $32 |
| Eisai Inc. | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Stryker | 1 | $25 |
| QOL Medical, LLC | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Mylan Specialty L.p. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| GSK | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| Insulet Corporation | 1 | $12 |
| Seqirus USA Inc | 1 | $12 |
| Cequr Corporation | 1 | $8 |
How this compares
$2,225 in reported general payments places this provider in the 95th percentile of 1,024 emergency medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 126 | $19,176 |
| LinzessLinaclotide | 21 | $10,526 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $10,238 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 95 | $1,828 |
| Doxycycline Hyclate | 164 | $1,591 |
| Fluticasone Propionate | 90 | $1,208 |
| Celecoxib | 78 | $1,082 |
| Diclofenac Potassium | 48 | $987 |
| Cefdinir | 53 | $682 |
| Mupirocin | 75 | $657 |
| Clonazepam | 47 | $638 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $633 |
| Diazepam | 25 | $595 |
| Ibuprofen | 56 | $577 |
| Azithromycin | 146 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $185 | $10,52621 claims |
| AstraZenecaBreztri Aerosphere | $70 | $10,23816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,024 emergency medicine providers in South Carolina.
Other emergency medicine in Sumter
- Christopher MichaelisMount Pleasant$399K
- Phillip MoschellaGreenville$298K
- Gregory HallCharleston$198K
- Heather BrownColumbia$123K
- Sarah FabianoGreenville$78K
- Timothy GregoryCharleston$40K
- Nicole NadelDaniel Island$29K
- Daniel TrohaColumbia$29K
- Patrick OmalleyLexington$23K
- Brian CruzFlorence$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.